Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in BXPC-3 and PANC-1 human pancreatic cancer cells.

about

Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in BXPC-3 and PANC-1 human pancreatic cancer cells.

Item

http://www.wikidata.org/entity/Q36230591

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Schedule-dependent cytotoxic s ...... human pancreatic cancer cells.

@ast

Schedule-dependent cytotoxic s ...... human pancreatic cancer cells.

@en

type

Item

label

Schedule-dependent cytotoxic s ...... human pancreatic cancer cells.

@ast

Schedule-dependent cytotoxic s ...... human pancreatic cancer cells.

@en

prefLabel

Schedule-dependent cytotoxic s ...... human pancreatic cancer cells.

@ast

Schedule-dependent cytotoxic s ...... human pancreatic cancer cells.

@en

P1476

Schedule-dependent cytotoxic s ...... human pancreatic cancer cells.

@en

P2093

Lin Wang

http://www.w3.org/2001/XMLSchema#string

Wei-Min Zhang

http://www.w3.org/2001/XMLSchema#string

Wen-Ying Zhang

http://www.w3.org/2001/XMLSchema#string

Zhi-Xia Zhu

http://www.w3.org/2001/XMLSchema#string

P2860

Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Epidemiology of pancreatic cancer

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer.

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.

Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications.

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

The ErbB/HER receptor protein-tyrosine kinases and cancer.

P304

969-975

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/ETM.2011.293

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22977607

http://www.w3.org/2001/XMLSchema#string

P932

3440689

http://www.w3.org/2001/XMLSchema#string